Investments in artificial intelligence to triple, as firms seek payday

Worldwide spending on cognitive and artificial intelligence systems is expected to triple over the next three years, as organizations invest in projects that use cognitive/AI software capabilities, according to a recent report from International Data Corporation. Spending on cognitive and AI systems will reach $ 77.6 billion in 2022. That’s up more than three times… Read More »

New Drug Approved for Traveler's Diarrhea

Nov. 20, 2018 — The FDA has approved a new prescription drug for traveler’s diarrhea, which affects millions of people a year, cutting short vacations and other trips. Rifamycin (Aemcolo) is expected to be on the market by mid-February, says Tom Joyce, president and CEO of Aries Pharmaceuticals, the U.S. firm licensed to distribute it… Read More »